Free Trial

AMBI Q2 2024 Earnings Report

AMBI EPS Results

Actual EPS
$0.24
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

AMBI Revenue Results

Actual Revenue
$142.09 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

AMBI Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

AMBI Earnings Headlines

EU’s Action Takes Aim At US Retirees
Trump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and global powers like China, Russia, and even Europe rapidly moving away from the U.S. dollar, central banks and financial giants are frantically buying gold at historic rates. This massive shift threatens your retirement savings with inflation and market instability—potentially worse than 2008. But you can protect yourself today by leveraging a little-known IRS loophole that lets you diversify your IRA or 401(k) into gold—tax-free and penalty-free.
See More AMBI Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AMBI? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AMBI and other key companies, straight to your email.

About AMBI

AMBI (NASDAQ:AMBI)t Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company's lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company's second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company's third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.

View AMBI Profile

More Earnings Resources from MarketBeat